GEN Exclusives

More »

GEN News Highlights

Back to Item »

Teva Outbids Valeant with $6.8B for Acquisition of Cephalon

Teva's $81.50 per share offer has been accepted by Cephalon's board, which had shunned Valeant's $73 per share proposal.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?